These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 1594809)

  • 1. A decision-theoretic evaluation of early stopping rules.
    Heitjan DF; Houts PS; Harvey HA
    Stat Med; 1992 Mar; 11(5):673-83. PubMed ID: 1594809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statistical rules for safety monitoring in clinical trials.
    Martens MJ; Logan BR
    Clin Trials; 2024 Apr; 21(2):152-161. PubMed ID: 37877375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bayesian decision sequential analysis with survival endpoint in phase II clinical trials.
    Zhao L; Woodworth G
    Stat Med; 2009 Apr; 28(9):1339-52. PubMed ID: 19226557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One-sided sequential stopping boundaries for clinical trials: a decision-theoretic approach.
    Berry DA; Ho CH
    Biometrics; 1988 Mar; 44(1):219-27. PubMed ID: 3358990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early stopping rules and long-term follow-up in phase III trials.
    Pignon JP; Arriagada R
    Lung Cancer; 1994 Mar; 10 Suppl 1():S151-9. PubMed ID: 8087505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
    Lewis RJ; Lipsky AM; Berry DA
    Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stopping rules for phase II studies.
    Stallard N; Whitehead J; Todd S; Whitehead A
    Br J Clin Pharmacol; 2001 Jun; 51(6):523-9. PubMed ID: 11422011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decision-theoretic designs for small trials and pilot studies: A review.
    Hee SW; Hamborg T; Day S; Madan J; Miller F; Posch M; Zohar S; Stallard N
    Stat Methods Med Res; 2016 Jun; 25(3):1022-38. PubMed ID: 26048902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequentist evaluation of group sequential clinical trial designs.
    Emerson SS; Kittelson JM; Gillen DL
    Stat Med; 2007 Dec; 26(28):5047-80. PubMed ID: 17573678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Flexible implementations of group sequential stopping rules using constrained boundaries.
    Burington BE; Emerson SS
    Biometrics; 2003 Dec; 59(4):770-7. PubMed ID: 14969454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reporting on data monitoring committees in neonatal randomised controlled trials is inconsistent.
    Perrem LM; Gosling S; Ravikumar I; Khashan AS; Miletin J; Ryan CA; Dempsey E
    Acta Paediatr; 2017 Jan; 106(1):30-33. PubMed ID: 27637413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An analysis of protocols and publications suggested that most discontinuations of clinical trials were not based on preplanned interim analyses or stopping rules.
    Stegert M; Kasenda B; von Elm E; You JJ; Blümle A; Tomonaga Y; Saccilotto R; Amstutz A; Bengough T; Briel M;
    J Clin Epidemiol; 2016 Jan; 69():152-60. PubMed ID: 26361993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Practical problems in interim analyses, with particular regard to estimation.
    Pocock SJ; Hughes MD
    Control Clin Trials; 1989 Dec; 10(4 Suppl):209S-221S. PubMed ID: 2605969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Performance of Fixed-Horizon, Look-Ahead Procedures Compared to Backward Induction in Bayesian Adaptive-Randomization Decision-Theoretic Clinical Trial Design.
    Lipsky AM; Lewis RJ
    Int J Biostat; 2019 Feb; 15(1):. PubMed ID: 30726189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantifying the bias in the estimated treatment effect in randomized trials having interim analyses and a rule for early stopping for futility.
    Walter SD; Han H; Briel M; Guyatt GH
    Stat Med; 2017 Apr; 36(9):1506-1518. PubMed ID: 28183155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Information time scales for interim analyses of randomized clinical trials.
    Freidlin B; Othus M; Korn EL
    Clin Trials; 2016 Aug; 13(4):391-9. PubMed ID: 27136947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving Probabilities of Correct Interim Decision in Population Enrichment Designs.
    Götte H; Donica M; Mordenti G
    J Biopharm Stat; 2015; 25(5):1020-38. PubMed ID: 24914474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Designing a series of decision-theoretic phase II trials in a small population.
    Hee SW; Stallard N
    Stat Med; 2012 Dec; 31(30):4337-51. PubMed ID: 22927289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Roaming through the methodology. XIV. The premature ending of a randomized trial].
    Vandenbroucke JP
    Ned Tijdschr Geneeskd; 1999 Jun; 143(25):1305-8. PubMed ID: 10416484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interim analyses and stopping rules in cancer clinical trials.
    Whitehead J
    Br J Cancer; 1993 Dec; 68(6):1179-85. PubMed ID: 8260370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.